Radiosurgery guided by a special scan added to Tumor Treating Fields for recurrent glioblastoma
Compares Tumor Treating Fields with or without targeted radiosurgery in adults with recurrent glioblastoma.
Key facts
- Who runs it
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
- Where
- Bydgoszcz, PolandSee the site
- Trial code
- Registry title
- TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
- Status
- Recruiting
- People taking part
- 92 people, planned
- Started
- 30 Dec 2025
- Expected to end
- Jun 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tumor Treating Fields (TTFields)
- FET-PET-Guided Stereotactic Radiosurgery
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose IDH-wildtype glioblastoma has come back after radiotherapy and temozolomide. It compares TTFields alone with TTFields plus FET-PET-guided stereotactic radiosurgery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- IDH-wildtype glioblastoma that is back for the first, second or third time, with a contrast-enhancing lesion on MRI that is 5 cm (2 in) or smaller. Karnofsky Performance Status 70 or higher.
- Earlier treatment
- Must have had radiotherapy and temozolomide, with at least 6 months since the radiotherapy ended. Must not have had bevacizumab or stereotactic re-irradiation in the planned treatment field.
- Biomarker or test result
- Molecular profile must be available, including IDH and MGMT status. The tumor must be IDH-wildtype.
Main reasons for not taking part
- Previous bevacizumab treatment
- More than three recurrences
- Implanted pacemaker, defibrillator, deep brain stimulator or other incompatible electronic device
- Pregnancy or breastfeeding
- Active intracranial hemorrhage
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Age ≥18 years
- Karnofsky Performance Status ≥70
- Histologically confirmed IDH-wildtype glioblastoma
- First, second, or third recurrence
- Radiological recurrence according to RANO 2.0 criteria
- Prior radiotherapy and temozolomide treatment
- At least 6 months since completion of previous radiotherapy
- Contrast-enhancing recurrent lesion visible on MRI
- Maximum recurrent lesion diameter ≤5 cm
- Available molecular profile including IDH and MGMT status
- Adequate hematologic, renal, and hepatic function
- Written informed consent
Who cannot take part
- Previous bevacizumab treatment
- Planned chemotherapy or targeted therapy after study intervention
- Previous stereotactic re-irradiation within the planned treatment field
- Significant psychiatric disorders
- Significant unrelated neurological disease
- Active intracranial hemorrhage
- Uncontrolled hypertension
- More than three recurrences
- Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device
- Pregnancy or breastfeeding
- Severe renal dysfunction
- Participation in another interventional study likely to interfere with this study
This trial is currently available in Poland.
- Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology CenterBydgoszcz, PolandContact: Agnieszka Rydzewska, Study CoordinatorTaking people
About the trial
What the trial wants to find out
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
Read full original descriptionShow less
Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation.
The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.
The 2 groups in the trial
- TTFields Plus FET-PET-Guided Stereotactic RadiosurgeryTreatment being tested
Participants receive Tumor Treating Fields (TTFields) therapy combined with FET-PET-guided stereotactic radiosurgery (SRS) for recurrent IDH-wildtype glioblastoma. TTFields treatment is administered for four months. Stereotactic radiosurgery is delivered within 14 days after initiation of TTFields according to protocol-defined target volumes based on MRI and FET-PET imaging.
Treatment: Tumor Treating Fields (TTFields) and FET-PET-Guided Stereotactic Radiosurgery
- TTFields AloneExisting treatment, for comparison
Participants receive Tumor Treating Fields (TTFields) therapy alone for recurrent IDH-wildtype glioblastoma according to standard clinical practice. TTFields treatment is administered for four months.
Treatment: Tumor Treating Fields (TTFields)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tumor Treating Fields (TTFields) Concomitant With Stereotactic Radiosurgery Based on FET-PET vs TTFields Alone for the Treatment of Recurrent, Glioblastoma (Tarrget 2.0)
- Plain-language title
- Radiosurgery guided by a special scan added to Tumor Treating Fields for recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 June 2026